Cargando…

Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series

BACKGROUND: Pericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis. CASE PRESENTATION: We present case series of 4 patients with purulent pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Dybowska, Małgorzata, Szturmowicz, Monika, Opoka, Lucyna, Rudziński, Piotr, Tomkowski, Witold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451238/
https://www.ncbi.nlm.nih.gov/pubmed/32854624
http://dx.doi.org/10.1186/s12872-020-01674-z
_version_ 1783574943775064064
author Dybowska, Małgorzata
Szturmowicz, Monika
Opoka, Lucyna
Rudziński, Piotr
Tomkowski, Witold
author_facet Dybowska, Małgorzata
Szturmowicz, Monika
Opoka, Lucyna
Rudziński, Piotr
Tomkowski, Witold
author_sort Dybowska, Małgorzata
collection PubMed
description BACKGROUND: Pericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis. CASE PRESENTATION: We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA) was used. Management of PP requires a combined surgical and medical approach. The most important is complete drainage of the effusion by subxiphoid pericardiotomy connected with complementary use of broad-spectrum antibiotics. Despite the use of broad- spectrum antibiotics, in some patients a large volume of daily drainage is still present. Constrictive pericarditis as a complication of PP is observed in majority of patients. Intrapericardial administration of fibrinolytic agents, although not strongly recommended, can improve efficacy of antibiotic treatment especially in patients with loculation fluid and can prevent the development of constrictive pericarditis. r-tPA was applied at a dose of 20 mg dissolved in 100 ml of normal saline in a 100 ml syringe, administered by a large pericardial drain (Pezzer drain) installed into the pericardial cavity during pericardioscopy. The tube was closed and re-opened after 24 h. No serious complications, such as bleeding, allergy or hypotension, were noted. CONCLUSION: We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA), prevented the development of constrictive pericarditis, and increased efficacy of antibiotic treatment without any significant complications.
format Online
Article
Text
id pubmed-7451238
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74512382020-08-28 Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series Dybowska, Małgorzata Szturmowicz, Monika Opoka, Lucyna Rudziński, Piotr Tomkowski, Witold BMC Cardiovasc Disord Case Report BACKGROUND: Pericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis. CASE PRESENTATION: We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA) was used. Management of PP requires a combined surgical and medical approach. The most important is complete drainage of the effusion by subxiphoid pericardiotomy connected with complementary use of broad-spectrum antibiotics. Despite the use of broad- spectrum antibiotics, in some patients a large volume of daily drainage is still present. Constrictive pericarditis as a complication of PP is observed in majority of patients. Intrapericardial administration of fibrinolytic agents, although not strongly recommended, can improve efficacy of antibiotic treatment especially in patients with loculation fluid and can prevent the development of constrictive pericarditis. r-tPA was applied at a dose of 20 mg dissolved in 100 ml of normal saline in a 100 ml syringe, administered by a large pericardial drain (Pezzer drain) installed into the pericardial cavity during pericardioscopy. The tube was closed and re-opened after 24 h. No serious complications, such as bleeding, allergy or hypotension, were noted. CONCLUSION: We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA), prevented the development of constrictive pericarditis, and increased efficacy of antibiotic treatment without any significant complications. BioMed Central 2020-08-27 /pmc/articles/PMC7451238/ /pubmed/32854624 http://dx.doi.org/10.1186/s12872-020-01674-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Dybowska, Małgorzata
Szturmowicz, Monika
Opoka, Lucyna
Rudziński, Piotr
Tomkowski, Witold
Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
title Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
title_full Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
title_fullStr Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
title_full_unstemmed Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
title_short Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
title_sort intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451238/
https://www.ncbi.nlm.nih.gov/pubmed/32854624
http://dx.doi.org/10.1186/s12872-020-01674-z
work_keys_str_mv AT dybowskamałgorzata intrapericardialrecombinanttissueplasminogenactivatorinpurulentpericarditiscaseseries
AT szturmowiczmonika intrapericardialrecombinanttissueplasminogenactivatorinpurulentpericarditiscaseseries
AT opokalucyna intrapericardialrecombinanttissueplasminogenactivatorinpurulentpericarditiscaseseries
AT rudzinskipiotr intrapericardialrecombinanttissueplasminogenactivatorinpurulentpericarditiscaseseries
AT tomkowskiwitold intrapericardialrecombinanttissueplasminogenactivatorinpurulentpericarditiscaseseries